Carl Zeiss Meditec AG announces agreement to acquire D.O.R.C. | Press Release

Zuidland, The Netherlands, | Dec. 15, 2023

Carl Zeiss Meditec AG announced today that they have entered into an agreement to acquire 100% of the shares in D.O.R.C. Dutch Ophthalmic Research Center (International) B.V. from its current owner Eurazeo SE, Paris, France.

The acquisition will enhance and complement ZEISS Medical Technology’s broad ophthalmic portfolio and range of digitally connected workflow solutions for addressing a wide variety of eye conditions, including retinal disorders, cataracts, glaucoma and refractive errors. It will also give the company access to one of the market’s most advanced dual-function systems - the EVA NEXUSTM platform. EVA NEXUSTM is the core of a strong portfolio, comprising of a dual-capable system and a full range of accessories, instruments and liquids offering a best-in-class solution across VR, cataract, and combined procedures, ensuring surgeons can rely on a single platform to cater to a variety of procedure types.

“With the acquisition of Dutch Ophthalmic Research Center, we’ll bring together two highly innovative ophthalmic powerhouses to accelerate ZEISS’s position in the vitreo-retinal surgery segment and extend our leadership in the ophthalmic medical devices market,” says Dr. Markus Weber, President and CEO of Carl Zeiss Meditec AG.

“In the year when D.O.R.C. celebrates 40 years of surgeon-inspired innovation in ophthalmic surgery, we could not be more excited to join a market leader and visionary like ZEISS Medical Technology,” says Pierre Billardon, CEO of D.O.R.C. “We’ve built an amazing business with innovative, market-leading products and look forward to seizing this opportunity for growth and advancing the future of ophthalmic surgery. I am personally proud and immensely grateful to all of the team at D.O.R.C. for their commitment and expertise to help patients see again.”

The transaction remains subject to applicable regulatory and antitrust approvals.

About D.O.R.C. Dutch Ophthalmic Research Center (International) B.V.

D.O.R.C. is one of the world’s leading suppliers of equipment, instruments and liquids for ophthalmic surgery. For 40 years, D.O.R.C. has grown into a successful international business, shaping its product portfolio through close collaboration with leading top surgeons. The company improves eye surgery globally and maximizes surgeon control by providing innovative quality approaches for eye disorders. Its products are exported to more than 80 countries worldwide. D.O.R.C. is headquartered in Zuidland, the Netherlands, and has more than 750 employees.

www.dorcglobal.com

About Carl Zeiss Meditec AG

Carl Zeiss Meditec AG (ISIN: DE0005313704), which is listed on the MDAX and TecDAX of the German stock exchange, is one of the world's leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. The Company offers complete solutions, including implants and consumables, to diagnose and treat eye diseases. The Company creates innovative visualization solutions in the field of microsurgery. With approximately 4,823 employees worldwide, the Group generated revenue of €2,089.3m in fiscal year 2022/23 (to 30 September).

The Group’s head office is located in Jena, Germany, and it has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Application and Research (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the Company's presence in these rapidly developing economies. Around 41 percent of Carl Zeiss Meditec AG’s shares are in free float. The remaining approx. 59 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries.

For further information visit: www.zeiss.com/med